Kelly Papadakis
Overview
Explore the profile of Kelly Papadakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghofrani H, Simonneau G, DArmini A, Fedullo P, Howard L, Jais X, et al.
Lancet Respir Med
. 2024 Mar;
12(4):e21-e30.
PMID: 38548406
Background: Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar. Methods: The phase 2, double-blind,...
2.
Mouthon L, Poiraudeau S, Vernon M, Papadakis K, Perchenet L, Khanna D
Arthritis Res Ther
. 2020 Jan;
22(1):3.
PMID: 31907061
Background: We aimed to develop a patient-reported outcome measure, in accordance with the US Food and Drug Administration guidance, to capture the impact of systemic sclerosis-related digital ulcers (SSc-DUs) on...
3.
Gatzoulis M, Landzberg M, Beghetti M, Berger R, Efficace M, Gesang S, et al.
Circulation
. 2018 Dec;
139(1):51-63.
PMID: 30586694
Background: Eisenmenger syndrome describes congenital heart disease-associated severe pulmonary hypertension accompanied by right-to-left shunting. The multicenter, double-blind, randomized, placebo-controlled, 16-week, phase III MAESTRO study (Macitentan in Eisenmenger Syndrome to Restore...
4.
Vachiery J, Delcroix M, Al-Hiti H, Efficace M, Hutyra M, Lack G, et al.
Eur Respir J
. 2018 Feb;
51(2).
PMID: 29437943
The MELODY-1 study evaluated macitentan for pulmonary hypertension because of left heart disease (PH-LHD) in patients with combined post- and pre-capillary PH.63 patients with PH-LHD and diastolic pressure gradient ≥7 ...
5.
Ghofrani H, Simonneau G, DArmini A, Fedullo P, Howard L, Jais X, et al.
Lancet Respir Med
. 2017 Sep;
5(10):785-794.
PMID: 28919201
Background: Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar. Methods: The phase 2, double-blind,...
6.
Khanna D, Denton C, Merkel P, Krieg T, Le Brun F, Marr A, et al.
JAMA
. 2016 May;
315(18):1975-88.
PMID: 27163986
Importance: Digital ulcers in patients with systemic sclerosis are associated with pain and poor quality of life. Endothelin-1 promotes vasculopathy in systemic sclerosis after macitentan, an endothelin-1 blocker. Objective: To...
7.
Durgam S, Litman R, Papadakis K, Li D, Nemeth G, Laszlovszky I
Int Clin Psychopharmacol
. 2015 Dec;
31(2):61-8.
PMID: 26655732
This 6-week, double-blind, placebo-controlled, proof-of-concept study evaluated the efficacy, safety, and tolerability of low-dose (1.5-4.5 mg/day) and high-dose (6-12 mg/day) cariprazine in patients with acute exacerbation of schizophrenia (NCT00404573). The...
8.
Keck Jr P, Hsu H, Papadakis K, Russo Jr J
Clin Neuropharmacol
. 2009 Jul;
32(4):199-204.
PMID: 19620854
Objective: Evaluate the efficacy and tolerability of memantine (20, 30, and 40 mg/d) in the acute treatment of adults with bipolar I disorder hospitalized for mania. Methods: This multicenter, open-label,...
9.
Lieberman J, Papadakis K, Csernansky J, Litman R, Volavka J, Jia X, et al.
Neuropsychopharmacology
. 2008 Nov;
34(5):1322-9.
PMID: 19005465
Memantine, an uncompetitive antagonist of glutamate receptors of the N-methyl-D-aspartate type is approved for the treatment of moderate to severe Alzheimer's disease. A growing body of evidence supports a link...